The Impact of Matching to Psychotherapy Preference on Engagement in a Randomized Controlled Trial for Patients With Advanced Cancer.
The Impact of Matching to Psychotherapy Preference on Engagement in a Randomized Controlled Trial for Patients With Advanced Cancer.
复制标题
匹配心理治疗偏好对晚期癌症患者参与随机对照试验的影响。
DOI：
10.3389/fpsyg.2021.637519
复制
发表时间：
2021
影响因子：
3.8
通讯作者：
Breitbart W
中科院分区：
文献类型：
--
作者：
Marziliano A;Applebaum A;Moyer A;Pessin H;Rosenfeld B;Breitbart W
目的：本研究检验了随机分配到首选治疗组的患者是否比随机分配到非首选治疗组的患者对治疗的参与度更高。方法：数据来自一项随机对照试验，该随机对照试验比较了晚期癌症患者的个体意义中心心理治疗（IMCP）与个体支持性心理治疗（ISP）。随着患者对与治疗师的治疗联盟和参加的治疗课程的看法，治疗参与得以实施。使用两个 2 × 2 方差分析 (ANOVA) 模型，以治疗偏好（IMCP 与 ISP）和治疗分配（IMCP 与 ISP）作为自变量，以工作联盟和参加的会议次数作为结果变量。结果：倾向于 IMCP 并被分配到 IMCP 的患者报告的联盟明显强于那些倾向于 IMCP 但被分配到 ISP 的患者。结论：除了 IMCP 对晚期癌症患者的吸引力之外，本研究的结果对心理治疗研究具有更广泛的影响。喜欢新的心理治疗但接受标准治疗的患者可能比喜欢标准但接受新疗法的患者经历更弱的联盟。试验注册：Clinicaltrial.gov ID：NCT01323309
Objective: This study examined whether patients who were randomly assigned to their preferred therapy arm had stronger engagement with their treatment than those who were randomly assigned to a non-preferred therapy arm. Method: Data were drawn from a RCT comparing Individual Meaning-Centered Psychotherapy (IMCP), with Individual Supportive Psychotherapy (ISP), in patients with advanced cancer. Treatment engagement was operationalized as patients' perceptions of the therapeutic alliance with their therapist and therapy sessions attended. Two 2 by 2 Analysis of Variance (ANOVA) models were used, with treatment preference (IMCP vs. ISP) and treatment assignment (IMCP vs. ISP) as the independent variables and working alliance and number of sessions attended as outcome variables. Results: Patients who preferred and were assigned to IMCP reported a significantly stronger alliance than those who preferred IMCP but were assigned to ISP. Conclusions: The findings from this study have broader implications for research on psychotherapy beyond the appeal of IMCP in advanced cancer patients. Patients who prefer a novel psychotherapy that they cannot engage in elsewhere, but receive the standard treatment may experience weaker alliance than patients who prefer the standard but receive the novel therapy. Trial registration: Clinicaltrial.gov ID: NCT01323309
登录
查看更多内容
影响因子：
3.9
作者：
HORVATH, AO;GREENBERG, LS
通讯作者：
GREENBERG, LS
影响因子：
6.2
作者：
Breitbart W;Pessin H;Rosenfeld B;Applebaum AJ;Lichtenthal WG;Li Y;Saracino RM;Marziliano AM;Masterson M;Tobias K;Fenn N
通讯作者：
Fenn N
影响因子：
5.9
作者：
Applebaum, Allison J.;DuHamel, Katherine N.;Redd, William H.
通讯作者：
Redd, William H.
影响因子：
5.9
作者：
Chambless, DL;Hollon, SD
通讯作者：
Hollon, SD
影响因子：
5.9
作者：
Iacoviello, Brian M.;McCarthy, Kevin Scott;Barber, Jacques P.
通讯作者：
Barber, Jacques P.